|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 186.00 SEK | +0.16% |
|
+4.72% | -6.67% |
| 17/06 | Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta | FW |
| 13/06 | BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review | MT |
Company Valuation: BioArctic AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,401 | 10,497 | 23,972 | 23,651 | 17,634 | 16,440 | - | - |
| Change | - | 24.95% | 128.37% | -1.34% | -25.44% | -6.77% | - | - |
| Enterprise Value (EV) 1 | 7,422 | 9,664 | 23,176 | 23,044 | 17,175 | 14,873 | 14,668 | 13,655 |
| Change | - | 30.21% | 139.82% | -0.57% | -25.47% | -13.4% | -1.38% | -6.91% |
| P/E ratio | -122x | -87.6x | -2,092x | 103x | -99.8x | 15.6x | 49.9x | 16.8x |
| PBR | 9.26x | 13.3x | 30.5x | 22.6x | 19.7x | 8.41x | 7.81x | 5.55x |
| PEG | - | -1.2x | 23.1x | -0x | 1x | -0x | -0.7x | 0x |
| Capitalization / Revenue | 127x | 454x | 104x | 38.4x | 68.5x | 8.63x | 13.4x | 8.29x |
| EV / Revenue | 113x | 418x | 101x | 37.4x | 66.7x | 7.8x | 12x | 6.89x |
| EV / EBITDA | -100x | -76.3x | -8,251x | 85x | - | 12.8x | 38.1x | 11.9x |
| EV / EBIT | -87.3x | -69.2x | -1,329x | 91.2x | -75.2x | 13.2x | 35.6x | 12.9x |
| EV / FCF | -70.8x | -66.7x | -522x | 76.2x | -50.1x | 7.27x | 118x | 12.1x |
| FCF Yield | -1.41% | -1.5% | -0.19% | 1.31% | -2% | 13.8% | 0.85% | 8.27% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.78 | -1.36 | -0.13 | 2.59 | -2 | 11.92 | 3.721 | 11.04 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 65.94 | 23.15 | 229.9 | 616 | 257.4 | 1,906 | 1,224 | 1,983 |
| EBITDA 1 | -74 | -126.6 | -2.809 | 271.1 | - | 1,160 | 385.1 | 1,151 |
| EBIT 1 | -85.01 | -139.7 | -17.44 | 252.6 | -228.5 | 1,127 | 412.2 | 1,061 |
| Net income 1 | -68.52 | -119.8 | -11.18 | 229.2 | -177.1 | 1,036 | 328.4 | 973.5 |
| Net Debt 1 | -979.2 | -832.5 | -795.3 | -606.6 | -458.7 | -1,567 | -1,773 | -2,786 |
| Reference price 2 | 95.40 | 119.20 | 272.00 | 267.80 | 199.50 | 185.70 | 185.70 | 185.70 |
| Nbr of stocks (in thousands) | 88,060 | 88,060 | 88,132 | 88,315 | 88,389 | 88,531 | - | - |
| Announcement Date | 04/02/21 | 03/02/22 | 03/02/23 | 14/02/24 | 13/02/25 | - | - | - |
1SEK in Million2SEK
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 15.59x | 7.8x | 12.82x | -.--% | 173.06Cr | ||
| 38.52x | 5.61x | 19.69x | 0.88% | 4.95TCr | ||
| 46.5x | 9.42x | 27.85x | 0.4% | 2.89TCr | ||
| 150.55x | 5.17x | 88.72x | -.--% | 2.85TCr | ||
| 21.74x | 2.52x | 10.71x | -.--% | 2.81TCr | ||
| 22.57x | 1.92x | 8.71x | 1.15% | 1.27TCr | ||
| 15.86x | 1.8x | 9.06x | -.--% | 1.17TCr | ||
| -41.39x | 15.31x | -47.96x | -.--% | 1.07TCr | ||
| 24.78x | 5.17x | 13.75x | 0.11% | 1.03TCr | ||
| -38.23x | 8.51x | 1970.82x | -.--% | 1TCr | ||
| Average | 25.65x | 6.32x | 211.42x | 0.25% | 1.92TCr | |
| Weighted average by Cap. | 42.09x | 5.88x | 126.34x | 0.37% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BIOA B Stock
- Valuation BioArctic AB
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition